Archynetys Live news trend intelligence
▲ Peaking Business

DEA bans sale and possession of 7-OH, scheduling kratom compound as Schedule I for 2 years

The DEA's ban on 7-OH, a kratom compound, has sparked legal challenges and concerns over addiction care.

By · Published August 28, 2026 at 05:27 UTC · Updated August 28, 2026 at 07:24 UTC

5sources
5articles
3velocity
+0%since first seen
2h agofirst detected

Evidence dossier

Intelligence passport

54/100 Developing

Developing signal: this page remains available for transparency, but Archynetys keeps it out of search discovery until it reaches the public evidence threshold of 55.

5distinct sources shown
3velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 3.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.

Source diversity sample: Medical Xpress · Bloomberg Law News · MedPage Today · Courthouse News · KATU.

How this dossier is built: methodology · AI policy · corrections.

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

What happened

The DEA has banned the sale and possession of 7-OH, a compound found in kratom, by scheduling it as a Schedule I substance for two years. The move has drawn immediate legal challenges. A kratom advocacy group has filed a lawsuit against the government, arguing that the ban threatens the market and consumer access.

The DEA's action follows a broader scheduling of widely available opioid compounds as controlled substances. The ban has raised questions about the availability of kratom products and the impact on addiction care. Medical Xpress coverage focuses on the latest developments in kratom availability and addiction treatment options.

The kratom industry and consumers await the outcome of the lawsuit. The DEA's scheduling decision could reshape the market for kratom products and influence future regulatory actions on similar compounds.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.

Coverage (5)

Questions people are asking

What is 7-OH?

7-OH is a compound found in kratom, a plant used for its stimulant effects and as an opioid substitute.

Why did the DEA schedule 7-OH as a Schedule I substance?

The DEA scheduled 7-OH as a Schedule I substance due to its opioid-like effects, aiming to control its availability and address potential addiction risks.

What is the legal challenge against the DEA's ban?

A kratom advocacy group has filed a lawsuit arguing that the ban threatens the market and consumer access to kratom products.

Topics

Kratom 7-OH DEA Schedule I Opioids

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →